HomeTagsPharmaceutical

pharmaceutical

SGX-LISTED COMPANIES

Oiltek International 1H FY2026 Profit Dips But Massive Order Book Promises More

A 20% Margin Squeeze vs. The RM 258.7 Million Backlog Underwriting Future Growth At first...
SGX-LISTED COMPANIES

Everything You Need To Know About The All-Link Air & Sea IPO

From $4M to $74M in Two Years The Singapore Exchange (SGX-ST) is set to welcome...
spot_img
Pharmaceutical

AstraZeneca expands diagnostics and AI to tackle late-stage cancer deaths

AstraZeneca is sharpening its long-term AstraZeneca cancer strategy with a combination of heavy research...
Pharmaceutical

AstraZeneca deploys AI to cut drug timelines by 30% and boost survival

AstraZeneca is stepping up its investment in AI drug discovery to shorten treatment timelines...
SGX-LISTED COMPANIES

The Reason The US Department Of War Awarded iX Biopharma A $41M Contract For A Painkiller

Beyond the Needle and the Pill The opioid epidemic remains one of the most significant...
SGX-LISTED COMPANIES

How Vietnam Is Negatively Impacting Hyphens Pharma’s Growth

The Southeast Asian Pharmaceutical Puzzle Navigating the healthcare landscape in Southeast Asia is often described...
SGX-LISTED COMPANIES

Tianjin Pharmaceutical Da Ren Tang Is Shrinking To Succeed In FY2025

How TJ DRT’s 33% Revenue "Loss" Fueled a 72% Margin Miracle and a Record...
SGX-LISTED COMPANIES

Why China Medical Systems FY2025 Profits Dropped Despite Growth

https://open.spotify.com/episode/3YAldvdzS4eXE4RzkN9M18?si=8a54594510534cfe 5 Game-Changing Takeaways from CMS’s 2025 Transformation For the Chinese pharmaceutical sector, 2025 was the...
SGX-LISTED COMPANIES

iX Biopharma’s Secret Shortcut To The US Medical Market – 1H FY2026

From Cash Burn to Bioavailability: How iX Biopharma Slashed Losses by 67% via a...
SGX-LISTED COMPANIES

Why This Tiny Lab Is Outpacing Global Giants

The $1.5 Trillion Green Transition’s Secret Weapon In the high-stakes theater of the modern economy,...
SGX-LISTED COMPANIES

The Secret To Lonza’s Massive FY2025 Growth

5 Key Takeaways from Lonza's Blockbuster 2025 Report Takeaway 1: Record-Breaking Growth That Beat Expectations The...
SGX-LISTED COMPANIES

One Asset Deal Changed Everything For Tianjin Da Ren Tang In Q3 2025

How Tianjin Da Ren Tang's Revenue Fell 35% While Its Profits Soared: 4 Surprising...
Pharmaceutical

BD tackles shortage in healthcare professionals with robot pharmacy technology

Singapore hospitals are deploying robotic pharmacy technology to ease healthcare workforce shortages, cut patient...
SGX-LISTED COMPANIES

iX Biopharma’s Robust FY2025 Performance and Strategic Outlook

iX Biopharma LTD achieved robust financial performance with significant revenue and gross profit growth,...

Latest articles

SGX-LISTED COMPANIES

Oiltek International 1H FY2026 Profit Dips But Massive Order Book Promises More

A 20% Margin Squeeze vs. The RM 258.7 Million Backlog Underwriting Future Growth At first...
SGX-LISTED COMPANIES

Everything You Need To Know About The All-Link Air & Sea IPO

From $4M to $74M in Two Years The Singapore Exchange (SGX-ST) is set to welcome...
SGX-LISTED COMPANIES

Seatrium 1H FY2026 Profit Surge & Series Build Strategy

A 158% Signal of Intent Seatrium Limited has signaled a decisive end to its recovery...
SGX-LISTED COMPANIES

Jardine Cycle & Carriage 1H FY2026 Profit Dips But Big Payouts Loom

Why Jardine Cycle & Carriage is Changing More Than Just Its Name The 2026 half-year...